Japanese late-onset breast cancer families: Their clinicopathological characteristics and absence of BRCA1 and BRCA2 germline mutations

Takehiro Okumura, Takashi Fukutomi, Hitoshi Tsuda, Yae Kanai, Toshikazu Ushijima, Sadako Akashi-Tanaka, Takeshi Nanasawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The causes and pathologic and prognostic phenotypes of late-onset familial breast cancers are still unknown. The purpose of this study was to document the clinicopathological features of late-onset familial breast cancers using genetic testing of BRCA1 and BRCA2. Methods: We analyzed 11 breast cancers from 10 patients from 8 Japanese late-onset Breast cancer families. Results: The average age of the patients was 55 years (range 43 to 89). Bilateral occurrence was noted in 2 patients (8%). All the tumors were invasive ductal carcinomas, except for 1 case of invasive lobular carcinoma. Tumor size ranged from 0.8 cm to 7.8 cm (median 2.3 cm) and lymph node metastasis occurred in 6 of the 11 patients (55%). Six (55%) of the 11 tumors were histologically grade 2 and 5 (45%) were histologically grade 3. Estrogen receptor (ER) positivity was 80% (8/10). Overexpression of c-erbB-2 and p53 protein was detected in 18% (2/11) and 9% (1/11) of the tumors, respectively. Five patients from 4 families received genetic testing but all were negative for BRCA 1 and BRCA2 germline mutations. All the patients were alive after a median follow-up period of 32 months, except for 1 patient. Conclusions: In this study, no germline mutations of BRCA1 or BRCA2 were detected. However, there was a tendency towards ER-positive tumors, but the positivity of p53 protein was considered to be lower then that of sporadic tumors.

Original languageEnglish
Pages (from-to)251-254
Number of pages4
JournalBreast Cancer
Volume5
Issue number3
DOIs
Publication statusPublished - 1998 Jul
Externally publishedYes

    Fingerprint

Keywords

  • BRCA1
  • BRCA2
  • Familial breast cancer
  • Late-onset

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this